Prostate Cancer

China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic following progression on androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Phillip J. Koo, MD, discusses new management strategies for patients with prostate cancer.

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Treatment with relugolix achieved a high rate of sustained testosterone suppression to castrate levels in patients with androgen-sensitive advanced prostate cancer, meeting the primary endpoint of the phase III HERO trial.

Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Phillip J. Koo, MD, discusses the use of conventional imaging as well as the next-generation imaging tools that have the potential to change the management of patients with recurrent prostate cancer.

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.